AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript

AxoGen (AXGN) Q1 Earnings Lag Estimates

Axogen, Inc. Reports First Quarter 2026 Financial Results

Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN

AxoGen, Inc. $AXGN Shares Sold by JPMorgan Chase & Co.

Exchange Traded Concepts LLC Sells 26,743 Shares of AxoGen, Inc. $AXGN

Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth

ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN

AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum

AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference

Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Axogen Q4: EPS Miss Amid Biologics Transition

Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

AxoGen (AXGN) Q4 Earnings Miss Estimates

HighMark Wealth Management Buys 158,855 Shares of Axogen Stock

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

Principal Financial Group Inc. Purchases 21,002 Shares of AxoGen, Inc. $AXGN

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Wasatch Micro Cap Fund Q4 2025 Performance Review

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Axogen Announces Proposed Public Offering of Common Stock

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Axogen CEO Axed 25,000 Shares From His Direct Holdings

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

FDA approves Axogen's nerve repair graft

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates

Axogen, Inc. Reports Third Quarter 2025 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN